PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 1, 1989American Journal of Hematology17 citations

Type II H von willebrand disease: New structural abnormality of plasma and platelet von willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity

View Full Paper
AFAugusto B. FedericiPMP.M. MannucciRLRossana Lombardi

Structured PICO

P
Population
A patient with prolonged bleeding time, normal von Willebrand factor antigen (vWF:Ag), and low borderline ristocetin cofactor (Ricof) levels, along with several family members.
I
Intervention
Desmopressin (DDAVP) treatment and multimeric analysis of plasma and platelet von Willebrand factor.
O
Outcome
Structural abnormality of plasma and platelet von Willebrand factor.surrogate

Identification of a new structural abnormality of von Willebrand factor, designated as type II H von Willebrand disease.

Abstract

In this study a new variant of type II von Willebrand disease is identified by multimeric analyses of increasing resolving power. Prior to multimeric analysis, the patient was misdiagnosed as carrying an undefined abnormality in platelet function because of his normal von Willebrand factor antigen (vWF:Ag) and low borderline ristocetin cofactor (Ricof) levels. Absence of the largest multimers from the patient's plasma and platelets was shown in a low-resolution system, but all the multimers were present in his relatives. An abnormality in the complex multimeric structure was demonstrated in both plasma and platelets with high-resolution agarose gels. The plasma of the proband and of several family members shows a broader central band with a minor, faster moving satellite band differing from the typical "triplet pattern" observed with normal plasma. Platelets show a "doublet" that runs with a mobility different from the "doublet" in normals. Therefore the proband may be either a homozygote or double heterozygote for this new abnormality. Treatment with desmopressin (DDAVP) on several occasions corrected the prolonged bleeding time of the patient only transiently. Factor VIII increased significantly, but vWF:Ag and Ricof responded poorly. We conclude that this vWF abnormality is different from those observed in the other variants (II A-G) previously described. Therefore the proposed designation for this new variant is type II H.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Federici et al. (1989) studied this question.

synapsesocial.com/papers/6a70d828febe604dd7099e26https://doi.org/10.1002/ajh.2830320409
Ask AI
Helpful
Bookmark
Share
View Full Paper